Home   Distributors   Careers   Contact


• State-of-the-art NOVOLIMUS™ eluting scaffold system
• Next generation in scaffold technology

learn more

Desolve | Novolimus Eluting Bioresorbable Coronary Scaffold System

• Eliminates the need for a primer coating
• Achieves a bare metal surface within 6–9 months
• Superior efficacy and excellent clinical safety


Desyne BD | Novolimus Eluting Coronary Stent System

• Improved performance
• Superior clinical efficacy and safety

learn more

The State of the Art Drug Eluting Stent

Unique Drug Agent Novolimus

Advanced Drug Coating/Polymer Technology
• Lowest polymer coating load2
• Reduced risk of adverse clinical events3
• Reliable performance with lower drug dose

Unique Drug Agent Novolimus

• Proprietary drug facilitates superior clinical efficacy5
• Established safety and performance
• Clinically proven 'olimus' drug family

About Elixir

Innovating Vascular Restoration™

Leading the Way to Next Generation DES Platforms

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, CA, specializes in developing products that combine state-of-the-art technology with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. Learn More...


In the News

Elixir Medical at TCT 2016

Pre-Register for the Symposium

Transforming PCI

DESolve is CE Mark approved; Not available for sale in the U.S.

DESolve NXT and Cx are not available for sale.

AMITY is not for sale. Clinical trial is required for AMI indication.

Prava is not for sale and developed by Akesys Medical.

The MedTech Strategist| Vol 2, Issue 12

Elixir Medical’s Contrarian Play in Cardiology: Go Bioresorbable or Go Home

Elixir Medical CEO Speaks on DESolve Platform

PCRTV - Elixir Medical - Motasim Sirhan

By viewing this video, you acknowledge that you are an international healthcare provider. DESolve is CE Mark approved. Not for sale in the U.S. PMN 293



Press Releases